

# **Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea — April 23, 2021**

## **Speakers and Panelists: Affiliations and Disclosures**

### **Laura H. Bachmann, MD, MPH, FIDSA**

Chief Medical Officer

Acting Deputy Division Director

Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP)

Centers for Disease Control and Prevention (CDC)

Atlanta, GA

### **Lindley Barbee, MD, MPH**

Assistant Professor, Infectious Diseases, University of Washington

Medical Director, Public Health -- Seattle & King County STD Program

Medical Consultant, CDC, Division of STD Prevention, Clinical Team

Seattle, WA

### **Kyle Bernstein, PhD, ScM**

Branch Chief, Epidemiology and Statistics

Division of STD Prevention, NCHHSTP

CDC

Atlanta, GA

### **Radu Botgros, MD**

Scientific Officer

Biological Health Threats and Vaccines Strategy

Clinical Studies and Manufacturing Task Force

European Medicines Agency (EMA)

Amsterdam, The Netherlands

### **Juan Bravo, PhD**

Senior Scientist, Clinical Pharmacology & Drug Metabolism

Debiopharm International SA

Lausanne, Switzerland

### **Sue Cammarata, MD**

Sr. Clinical Subject Matter Expert

Tunnell Government Services

Contractor Supporting Division of Clinical Development, BARDA

Washington, D.C.

**Ricardo Chaves, MD, PhD**  
Executive Medical Director  
Debiopharm International SA  
Lausanne, Switzerland

**Carolyn D. Deal, PhD**  
Chief, Enteric and Sexually Transmitted Infections Branch  
Division of Microbiology and Infectious Diseases (DMID)  
National Institute of Allergy and Infectious Diseases (NIAID), NIH  
Bethesda, MD

**Guennaelle Dieppois, PhD**  
Senior Scientist, Pharmacology & Screening  
Debiopharm International SA  
Lausanne, Switzerland

**George L. Drusano, MD**  
Professor of Medicine  
Director, Institute for Therapeutic Innovation  
College of Medicine  
University of Florida  
Lake Nona, FL

**Erin M. Duffy, PhD**  
R&D Chief  
CARB-X  
Boston University  
Boston, MA

**Ann E. Eakin, PhD**  
Senior Scientific Officer  
Office of Biodefense, Research Resources & Translational Research  
DMID, NIAID, NIH  
Bethesda, MD

**Scott Evans, PhD**  
Founding Chair and Professor, Department of Biostatistics and Bioinformatics  
Director of the Biostatistics Center  
Milken Institute School of Public Health  
The George Washington University  
Washington, DC

**John Farley, MD, MPH**

Director  
Office of Infectious Diseases (OID)  
OND, CDER, FDA  
Silver Spring, MD

**Helen Fifer, BMBS, MRCP, FRCPath**

Consultant Microbiologist  
Blood Safety, Hepatitis, STI & HIV Division  
National Infection Service  
Public Health England  
London, UK

**Steven Gelone, PharmD**

President & Chief Operating Officer  
Nabriva Therapeutics plc  
Fort Washington, PA

**Khalil Ghanem, MD, PhD**

Professor of Medicine  
Johns Hopkins University School of Medicine  
Baltimore, MD

**Matthew Golden, MD, MPH**

Professor of Medicine, University of Washington  
Director, PHSKC HIV/STD Program  
Director, UW Center for AIDS and STD (CFAS)  
Seattle, WA

**Thomas Hiltke, PhD**

Chief, Sexually Transmitted Infections Section  
Enteric and Sexually Transmitted Infections Branch  
DMID, NIAID, NIH  
Bethesda, MD

**Hiwot Hiruy, MD**

Medical Officer  
Division of Anti-Infectives (DAI), OID  
OND, CDER, FDA  
Silver Spring, MD

**Edward W. Hook III, MD**

Emeritus Professor of Infectious Disease  
Department of Medicine  
The University of Alabama at Birmingham  
Birmingham, AL

**Seong Jang, PhD**

Team Lead, Clinical Pharmacology  
Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP)  
OTS, CDER, FDA  
Silver Spring, MD

**Ann E. Jerse, PhD**

Professor and Vice Chair  
Department of Microbiology and Immunology  
Uniformed Services University  
Bethesda, MD

**Peter Kim, MD**

Lead Medical Officer  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

**Jeff Klausner, MD, MPH**

Clinical Professor of Preventive Medicine  
Division of Disease Prevention, Policy and Global Health  
Department of Preventive Medicine  
University of Southern California Keck School of Medicine  
Los Angeles, CA

**Jeanne Marrazzo, MD, MPH, FACP, FIDSA**

Director, Division of Infectious Diseases  
C. Glenn Cobbs, M.D., Endowed Chair in Infectious Diseases  
University of Alabama at Birmingham School of Medicine  
Birmingham, AL

**Candice J. McNeil, MD, MPH, FAAP, FACP**

Associate Professor, Department of Medicine, Section on Infectious Diseases  
Wake Forest Baptist Health  
Co-Medical Director, Southeast STD/HIV PTC  
Consultant Medical Director, Forsyth County Department of Public Health  
Winston-Salem, NC

**Sumathi Nambiar, MD, MPH**

Director  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

**CAPT Lori Newman, MD**

US Public Health Service  
Medical Officer, Enteric and Sexually Transmitted Infections Branch  
DMID, NIAID, NIH  
Rockville, MD

**Seamus O'Brien, PhD**

Research & Development Director  
Global Antibiotic Research and Development Partnership (GARDP)  
Geneva, Switzerland

**Caroline Perry PhD**

Sr Director Clinical Development  
GlaxoSmithKline  
1250 South Collegeville Road  
Collegeville, PA 19426, USA

**Hilary E. L. Reno, MD, PhD**

Associate Professor of Medicine, Division of Infection Diseases  
John T. Milliken Department of Internal Medicine  
Washington University School of Medicine in St. Louis  
Medical Director, St. Louis County Sexual Health Clinic  
Medical Director, St. Louis STD/ HIV Prevention Training Center  
Director, St. Louis STI Regional Response Coalition  
St. Louis, MO

**Kerian Grande Roche, PhD**

Clinical Microbiology Reviewer  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

**Raul A. Romaguera, DMD, MPH**

Acting Division Director  
Division of STD Prevention, NCHHSTP  
CDC  
Atlanta, GA

**Dan Rubin, PhD**

Statistical Reviewer  
Division of Biometrics IV (DBIV), Office of Biostatistics (OB)  
OTS, CDER, FDA  
Silver Spring, MD

**Junko Sato, PhD**

Office Director  
Office of International Programs  
Pharmaceuticals and Medical Devices Agency (PMDA)  
Tokyo, Japan

**Nicole Scangarella-Oman, MS**

Scientific Director  
Diagnostics & Clinical Microbiology  
Antibacterials R&D  
Infectious Diseases Research Unit (IDRU)  
GlaxoSmithKline  
Collegeville, PA

**Olusegun Soge, MSc, PhD**

Assistant Professor, Departments of Global Health and Medicine  
Director, Neisseria Reference Laboratory  
University of Washington  
Seattle, WA

**Magnus Unemo, PhD**

Associate Professor,  
Director, WHO Collaborating Centre for Gonorrhoea and Other STIs,  
National Reference Laboratory for STIs,  
Department of Laboratory Medicine, Microbiology,  
Örebro University Hospital,  
Örebro, Sweden

**Brian VanScoy**

Director of Laboratory Operations  
Institute for Clinical Pharmacodynamics, Inc.  
Schenectady, NY

**Teodora Elvira C. Wi, MD**

Medical Officer, STI  
Global HIV, Hepatitis and STIs Programmes  
World Health Organization (WHO)  
Geneva, Switzerland

**Kimberly Workowski, MD**

Professor of Medicine  
Division of Infectious Diseases  
Emory University  
Atlanta, GA

**Yuliya Yasinskaya, MD**

Lead Medical Officer  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

**Jonathan M. Zenilman, MD**

Professor of Medicine, Division of Infectious Diseases  
Johns Hopkins University School of Medicine  
Johns Hopkins Bayview Medical Center  
Baltimore, MD

**Disclosures**

**Dr. Barbee** has received research support in the form of in-kind test kits from Hologic, and as grant support to the University of Washington from SpeedX and Nabriva. She has also served as a consultant to Nabriva

**Dr. Bravo** is a full-time employee of Debiopharm International SA.

**Dr Cammarata** is currently a full-time employee of Tunnell Government Services, acting as Senior Clinical Subject Matter Expert Supporting Biomedical Advanced Research & Development Authority (BARDA), Division of Clinical Development (DCD)

**Dr. Dieppois** is a full-time employee of Debiopharm international SA

**Erin Duffy** is a full-time employee of CARB-X, Boston University.

**Scott Evans** receives grant support from the National Institutes of Health (NIH). He has received travel support from the American Statistical Association; FDA; Osaka University; National Cerebral and Cardiovascular Center of Japan; Society for Clinical Trials; the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); the Deming Conference on Applied Statistics; Clinical Trials Transformation Initiative (CTTI); Antimicrobial Resistance and Stewardship Conference; and the Council for International Organizations of Medical Sciences (CIOMS). He receives royalties from Taylor and Francis and funding for editorial activities from DeGruyter. He is a consultant to Takeda, Pfizer, Roche, Novartis, Genentech, Amgen, AstraZeneca, Teva, Austrian Breast & Colorectal Cancer Study Group (ABCESG)/Breast International Group (BIG) and the Alliance Foundation Trials (AFT), Vir, Alexion, Gilead, Tracon, Advantagene, Microbiotix, Stryker, Atricure, International Drug Development Institute, Roivant, Neovasc, Nobel Pharma, Horizon, Rakuten, Duke University, University of Pennsylvania, Nuvelution, Abbvie, Clover, FHI Clinical, Lung Biotech, SAB Biopharm, and SVB LEERINK.

**Edward Hook** is a consultant to the Global Antibiotic Research and Development Partnership (GARDP) and VISBY diagnostics.

**Steve Gelone** is a director and employee of Nabriva Therapeutics and a director at Ribovate Therapeutics.

**Ann Jerse** has or is currently conducting *in vivo* efficacy testing of products against gonorrhea in animal models developed by my laboratory for Glaxo-Smith-Kline, Microbiotx, Inc., Reoxcyn Discoveries Group, Tetrphase, Inc., VenatoRx, and Yaso Therapeutics. These studies are funded by cooperative research and development agreements (CRADAs) or subcontracts to NIH grants

**Jeffrey Klausner** has received research grants from Glaxo Smith Kline, Cepheid, Visby Medical and donated research supplies from Hologic. He has received consulting fees from AIDS Healthcare Foundation, Curative, Talis Biomedical and SpeedX. He has received advisory board fees from Glaxo Smith Kline, Roche, Cepheid and Danaher.

**Candice McNeil** has received grants/research funding from the Biomedical Advanced Research and Development Authority (BARDA)/ GlaxoSmithKline (GSK), Becton Dickinson (BD), Centers for Disease Control and Prevention (CDC), Cepheid, Gilead, Hologic, and National Institutes of Health (NIH), paid to Wake Forest University Health Sciences.

**Seamus O'Brien** is a full-time employee of the GARDP foundation.

**Nicole Scangarella-Oman** is a full-time employee of GlaxoSmithKline

**Caroline Perry** is a full-time employee of GlaxoSmithKline.

**Olusegun Soge** has received grants from Hologic and SpeedX.

**Brian VanScoy** is a full-time employee of the Institute for Clinical Pharmacodynamics (ICPD). The Institute for Clinical Pharmacodynamics, Inc. has received research support from the following: Amlyx Pharmaceuticals, Inc., Arixa Pharmaceuticals, Arsanis Inc., Basilea, Pharmaceutica, B. Braun Medical Inc., BLC USA, Boston Pharmaceuticals, Cidara Therapeutics, Inc., Cipla, USA, Cumberland Pharmaceuticals, Debiopharm International SA, Discuva Limited, E-Scape Bio, Enhanced Pharmacodynamics, Entasis Therapeutics, Genentech, Geom Therapeutics, Inc., GlaxoSmithKline, Hoffmann-La Roche, Indalo Therapeutics, Insmid Inc., KBP Biosciences USA, Matinas, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Menarini, Ricerche S.p.A, Mutabilis, Nabriva Therapeutics AG, Naeja-RGM Pharmaceuticals, Novartis Pharmaceuticals Corp., NuCana Biomed, Paratek Pharmaceuticals, Inc., Polyphor, Ltd., PTC, Therapeutics, Sagimet, Spero Therapeutics, TauRx Therapeutics, Tetrphase Pharmaceuticals, Theravance Biopharma, USCAST, VenatoRx, Wockhardt Bio AG, Zogenix International.

**Kimberly Workowski:** Clinical trial research (STI)-DMID, Acuris, GSK, and Medical Consultant, CDC, Division of STD Prevention.

**Jonathan Zenilman** is a full-time employee of Johns Hopkins University and receives consulting fees from Pfizer as a member of several data safety monitoring boards for vaccine projects.